50378 Clinical efficacy of TAK-279, a highly selective oral tyrosine kinase 2 (TYK2) inhibitor, is associated with modulation of disease and TYK2 pathway biomarkers in patients with moderate-to-severe psoriasis

Saved in:
Bibliographic Details
Published in:Journal of the American Academy of Dermatology 2024-09, Vol.91 (3), p.AB159-AB159
Main Authors: Krueger, James G., Garcet, Sandra, Cheng, Jie, Kumar, Sachin, Blau, Jessamyn, Zhao, Yiwei, Zhang, Wenwen, Arunachalam, Vinayagam, Heap, Graham A., Thakker, Paresh, Choudhury, Amit
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0190-9622
DOI:10.1016/j.jaad.2024.07.632